Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study - Sorbonne Université Access content directly
Journal Articles Journal of Infection Year : 2022

Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study

Damien Le Dû
Joan-Pau Millet
  • Function : Author
Aliaksandr Skrahin
  • Function : Author
Graham Bothamley
  • Function : Author
Xavier Casas
  • Function : Author
Maria Musso
  • Function : Author
Alena Skrahina
  • Function : Author
Dzmitry Viatushka
  • Function : Author
Mathilde Jachym-Fréchet
  • Function : Author

Abstract

Objectives Limited evidence is available on the co-administration of treatment for hepatitis C virus (HCV) and multidrug-resistant tuberculosis (MDR-TB). The objective of this study is to assess safety and effectiveness of concomitant treatment of chronic HCV-infection and MDR-TB. Methods We performed a retrospective, multicentre observational cohort study of patients treated concomitantly for multidrug-resistant tuberculosis and HCV-infection between January 2015 and February 2021. Results Overall, 23 patients were enrolled across six centres in four countries. Predominant HCV genotype was 3 (40%) and most patients had absent or mild liver fibrosis. All patients completed HCV treatment without interruptions and achieved undetectable plasmatic HCV-RNA from week 12. Sustained virological response was equally obtained for all patients with available results. Among 11 patients who had finished MDR-TB treatment at data censoring, 10 achieved cure and one died. Overall, 18 liver-related adverse events were reported in 48% of patients, the majority (94%) occurring during MDR-TB treatment but before HCV treatment was started. No liver-related serious adverse events or Grade 4 adverse events were reported. Conclusions Concomitant treatment of HCV and MDR-TB was well tolerated and effective. HCV treatment should be considered in MDR-TB patients to reduce treatment-related hepatotoxicity and prevent progression of HCV-mediated liver disease.
Fichier principal
Vignette du fichier
Tunesi et al_Cotreatment for MDR-TB and HCV_letter_Title.pdf (285.62 Ko) Télécharger le fichier
MDR-HCV_Supplementary Tables_final.pdf (401.13 Ko) Télécharger le fichier
Origin Files produced by the author(s)
Origin Files produced by the author(s)

Dates and versions

hal-03608140 , version 1 (16-02-2023)

Identifiers

Cite

Simone Tunesi, Damien Le Dû, Gina Gualano, Joan-Pau Millet, Aliaksandr Skrahin, et al.. Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study. Journal of Infection, In press, 84 (6), pp.834--872. ⟨10.1016/j.jinf.2022.03.004⟩. ⟨hal-03608140⟩
56 View
81 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More